Investigations of the migraine-provoking effect of levcromakalim in patients with migraine with aura
Cephalalgia · 2024
DOI: 10.1177/03331024241237247 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Cephalalgia, 2024. Verfasst von Andreas Vinther Thomsen und 6 weiteren Autor:innen. Beteiligte Einrichtung: Danish Headache Center, Department of Neurology, Rigshospitalet - Glostrup, Faculty of Health and Medical Sciences, University of Copenhagen, Denmark. Hauptthemen laut MEDLINE: Migraine with Aura, Migraine Disorders, Epilepsy. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background/Hypothesis Experimental provocation studies have yielded important insights in migraine pathophysiology. Levcromakalim has been previously shown to induce migraine-like attacks with and without aura. In this study, we aim to further explore the migraine aura-inducing potential of levcromakalim.
Methods
In a double-blind, randomized, placebo-controlled cross-over study, 27 adult participants with migraine with aura received intravenous infusions of levcromakalim and saline. Headache, aura and associated symptoms were evaluated for 24 hours following administration of the study drug. The primary endpoint was occurrence of migraine-like attacks with or without aura in the 24-hour observation period.
Results
Thirteen participants developed migraine-like attacks on the active day only (P = 0.0098), and four participants developed aura on the active day only (P = 0.68). The median time to onset of migraine-like headache was three hours, and the median time to onset of aura was 27.5 minutes. Conclusion/Interpretation Our findings affirm the potent migraine-inducing effect of levcromakalim. We observed a lower induction-rate of migraine aura than previously reported. Further studies are warranted to identify predictors of migraine aura following levcromakalim. ClinicalTrials.gov identifier NCT04905654
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Danish Headache Center, Department of Neurology, Rigshospitalet - Glostrup, Faculty of Health and Medical Sciences, University of Copenhagen, Denmark.
- Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
- Department of Neurology, Copenhagen University Hospital - Herlev and Gentofte, Herlev, Denmark.
- Department of Clinical Immunology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
- Department of Clinical Immunology, Zealand University Hospital, Køge, Denmark.
- Novo Nordisk Foundation Center for Protein Research, Brunak Lab, Copenhagen University Hospital, Copenhagen, Denmark.
ORCID-Profile: Andreas Vinther Thomsen, Mohammad Al-Mahdi Al-Karagholi, Anders Hougaard, Sisse Rye Ostrowski
Zitieren
APA
Thomsen, A. V., Al-Karagholi, M. A., Hougaard, A., Ostrowski, S. R., Pedersen, O. B., Hansen, T. F., & Ashina, M. (2024). Investigations of the migraine-provoking effect of levcromakalim in patients with migraine with aura. Cephalalgia. https://doi.org/10.1177/03331024241237247
Vancouver
Thomsen AV, Al-Karagholi MA, Hougaard A, Ostrowski SR, Pedersen OB, Hansen TF, et al. Investigations of the migraine-provoking effect of levcromakalim in patients with migraine with aura. Cephalalgia. 2024. doi:10.1177/03331024241237247
BibTeX
@article{Thomsen2024,
author = {Thomsen, Andreas Vinther and Al-Karagholi, Mohammad Al-Mahdi and Hougaard, Anders and Ostrowski, Sisse Rye and Pedersen, Ole Birger and Hansen, Thomas Folkmann and Ashina, Messoud},
title = {Investigations of the migraine-provoking effect of levcromakalim in patients with migraine with aura},
journal = {Cephalalgia},
year = {2024},
doi = {10.1177/03331024241237247}
}
EUVIMED